​

Cara Therapeutics (CARA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CARA Stock Forecast

Cara Therapeutics (CARA) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $14.50, with a high of $30.00 and a low of $1.00. This represents a 172.56% increase from the last price of $5.32.

- $6 $12 $18 $24 $30 High: $30 Avg: $14.5 Low: $1 Last Closed Price: $5.32

CARA Stock Rating

Cara Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (69.23%), 4 Hold (30.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 4 9 Strong Sell Sell Hold Buy Strong Buy

CARA Price Target Upside V Benchmarks

TypeNameUpside
StockCara Therapeutics172.56%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$1.00
Last Closing Price$5.32$5.32$5.32
Upside/Downside---81.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--1--1
Mar, 25--1--1
Feb, 25--1--1
Jan, 25--2--2
Dec, 24--4--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 13, 2024Sumant KulkarniCanaccord Genuity$1.00$0.6847.06%-81.20%
Jun 12, 2024Annabel SamimyStifel Nicolaus$1.00$0.6847.06%-81.20%
May 10, 2022Oren LivnatH.C. Wainwright$30.00$9.23225.03%463.91%
Mar 03, 2022Joseph StringerNeedham$26.00$11.08134.66%388.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 13, 2024NeedhamBuyBuyhold
Jun 13, 2024H.C. WainwrightNeutraldowngrade
Jun 13, 2024NeedhamBuyHolddowngrade
Jun 13, 2024Canaccord GenuityUnderperformNegativedowngrade
May 14, 2024NeedhamBuyBuyhold
Mar 28, 2024NeedhamBuyBuyhold
Mar 05, 2024NeedhamBuyBuyhold
Dec 19, 2023Piper SandlerBuyBuyhold
Nov 14, 2023Piper SandlerOverweightNeutraldowngrade
Mar 07, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-19 $-13 $-7 $-1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.18$-1.74$-1.55$-2.19$-0.02----
Avg Forecast$-1.22$-1.67$-1.35$-24.07$-15.08$-8.82$-8.64$-13.44$-13.92
High Forecast$-0.56$-0.77$-1.35$-23.85$-15.08$-8.82$-8.64$-13.44$-13.92
Low Forecast$-2.27$-3.11$-1.35$-24.41$-15.08$-8.82$-8.64$-13.44$-13.92
Surprise %-114.75%4.19%14.81%-90.90%-99.87%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$135.08M$23.03M$41.87M$20.97M$7.14M----
Avg Forecast$28.07M$23.35M$53.45M$27.41M$7.15M$7.83M$10.16M$25.20M$30.11M
High Forecast$46.75M$38.89M$53.45M$29.53M$7.15M$7.83M$10.16M$25.20M$30.11M
Low Forecast$16.46M$13.70M$53.45M$25.72M$7.15M$7.83M$10.16M$25.20M$30.11M
Surprise %381.23%-1.39%-21.68%-23.49%-0.13%----

Net Income Forecast

$-850M $-640M $-430M $-220M $-10M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.41M$-88.19M$-83.41M$-118.51M$-70.87M----
Avg Forecast$91.72M$-90.35M$123.67M$-118.51M$-816.57M$-477.59M$-467.85M$-727.76M$-753.75M
High Forecast$142.03M$-41.78M$163.13M$-80.71M$-816.57M$-477.59M$-467.85M$-727.76M$-753.75M
Low Forecast$41.42M$-168.49M$84.22M$-156.32M$-816.57M$-477.59M$-467.85M$-727.76M$-753.75M
Surprise %-90.83%-2.39%-167.45%--91.32%----

CARA Forecast FAQ

Is Cara Therapeutics stock a buy?

Cara Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cara Therapeutics is a favorable investment for most analysts.

What is Cara Therapeutics's price target?

Cara Therapeutics's price target, set by 13 Wall Street analysts, averages $14.5 over the next 12 months. The price target range spans from $1 at the low end to $30 at the high end, suggesting a potential 172.56% change from the previous closing price of $5.32.

How does Cara Therapeutics stock forecast compare to its benchmarks?

Cara Therapeutics's stock forecast shows a 172.56% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Cara Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Cara Therapeutics’s EPS forecast?

Cara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-8.82, marking a 44000.00% increase from the reported $-0.02 in 2024. Estimates for the following years are $-8.64 in 2026, $-13.44 in 2027, and $-13.92 in 2028.

What is Cara Therapeutics’s revenue forecast?

Cara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $7.83M, reflecting a 9.66% increase from the reported $7.14M in 2024. The forecast for 2026 is $10.16M, followed by $25.2M for 2027, and $30.1M for 2028.

What is Cara Therapeutics’s net income forecast?

Cara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-478M, representing an 573.93% increase from the reported $-70.867M in 2024. Projections indicate $-468M in 2026, $-728M in 2027, and $-754M in 2028.